| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA888: Risankizumab for previously treated moderately to severely active Crohn's disease |
|
Medicine details |
|
| Medicine name | risankizumab (Skyrizi®) |
| Formulation | intravenous infusion |
| Reference number | 3892 |
| Indication | Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. |
| Company | AbbVie Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/10/2022 |
| NICE guidance | TA888: Risankizumab for previously treated moderately to severely active Crohn's disease |